Thermoelectric properties of Ca0.8Dy0.2MnO3 synthesized by solution combustion process

High-quality Ca0.8Dy0.2MnO3 nano-powders were synthesized by the solution combustion process. The size of the synthesized Ca0.8Dy0.2MnO3 powders was approximately 23 nm. The green pellets were sintered at 1150-1300°C at a step size of 50°C. Sintered Ca0.8Dy0.2MnO3 bodies crystallized in the perovskite structure with an orthorhombic symmetry. The sintering temperature did not affect the Seebeck coefficient, but significantly affected the electrical conductivity. The electrical conductivity of Ca0.8Dy0.2MnO3 increased with increasing temperature, indicating a semiconducting behavior. The absolute value of the Seebeck coefficient gradually increased with an increase in temperature. The highest power factor (3.7 × 10-5 Wm-1 K-2 at 800°C) was obtained for Ca0.8Dy0.2MnO3 sintered at 1,250°C. In this study, we investigated the microstructure and thermoelectric properties of Ca0.8Dy0.2MnO3, depending on sintering temperature

HER-2/neu diagnostics in breast cancer

HER-2/neu status of the primary breast cancer (PBC) is determined by immunohistochemistry and fluorescent in situ hybridization. Because of a variety of technical factors, however, the PBC may not accurately reflect the metastatic tumor in terms of HER-2/neu status. Recently published guidelines recommend that tumors be defined as HER-2/neu positive if 30% or more of the cells are 3+. Circulating levels of the HER-2 extracellular domain can be measured in serum using a test cleared by the US Food and Drug Administration, and increased serum HER-2/neu levels to above 15 ng/ml can reflect tumor progression. Studies comparing tissue HER-2/neu status of the PBC and HER-2/neu levels above 15 ng/ml in metastatic breast cancer patients are also reviewed

Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study

Standardized monitoring of BCR::ABL1 mRNA levels is essential for the management of chronic myeloid leukemia (CML) patients. From 2016 to 2021 the European Treatment and Outcome Study for CML (EUTOS) explored the use of secondary, lyophilized cell-based BCR::ABL1 reference panels traceable to the World Health Organization primary reference material to standardize and validate local laboratory tests. Panels were used to assign and validate conversion factors (CFs) to the International Scale and assess the ability of laboratories to assess deep molecular response (DMR). The study also explored aspects of internal quality control. The percentage of EUTOS reference laboratories (n = 50) with CFs validated as optimal or satisfactory increased from 67.5% to 97.6% and 36.4% to 91.7% for ABL1 and GUSB, respectively, during the study period and 98% of laboratories were able to detect MR4.5 in most samples. Laboratories with unvalidated CFs had a higher coefficient of variation for BCR::ABL1(IS) and some laboratories had a limit of blank greater than zero which could affect the accurate reporting of DMR. Our study indicates that secondary reference panels can be used effectively to obtain and validate CFs in a manner equivalent to sample exchange and can also be used to monitor additional aspects of quality assurance.</p

Deterioro cognitivo y horas de sueño en mayores de 65 años no institucionalizados: estudio en farmacia comunitaria

Objetivo: Determinar factores de riesgo, relacionados con el estilo de vida, asociados con la presencia de deterioro cognitivo en personas mayores de 65 años. Método: Para ello se diseñó un estudio observacional transversal con personas mayores de 65 años no institucionalizadas mediante entrevista personal estructurada. El estudio se realizó en 14 farmacias de la Comunidad Valenciana desde marzo 2011 hasta marzo de 2013. Se utilizan como test de cribado el Short Portable Mental State Questionnaire (SPMSQ) de Pfeiffer y el Mini-Mental State Examination (MMSE) versión NORMACODERM de Blesa. Se definió deterioro cognitivo por SPMSQ ≥ 3 (para analfabetos ≥ 4) y/o MMSE ≤ 24. Resultados: Participaron en el estudio 729 personas. Se encontró que el 17,6% de los participantes (n = 128) presentaban resultados compatibles con deterioro cognitivo. Se determinó que dormir 9 o más horas diarias es causa o consecuencia y, por tanto, un factor de riesgo y/o de alarma en el desarrollo de deterioro cognitivo en personas mayores de 65 años. El ejercicio físico y pocas horas de sueño no obtuvo relación con el deterioro cognitivo. Conclusión: El cambio de hábitos de sueño en el anciano (pasar a dormir más horas) es una señal de alerta para estudiar la presencia de un posible deterioro cognitivo